financetom
Business
financetom
/
Business
/
ArcBest Q4 Non-GAAP Earnings, Revenue Decline -- Shares Up Pre-Bell
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ArcBest Q4 Non-GAAP Earnings, Revenue Decline -- Shares Up Pre-Bell
Jan 31, 2025 4:05 AM

06:36 AM EST, 01/31/2025 (MT Newswires) -- ArcBest ( ARCB ) reported Q4 non-GAAP earnings Friday of $1.33 per diluted share, down from $2.47 a year earlier.

Analysts polled by FactSet expected $1.05.

Revenue for the quarter ended Dec. 31 was $1.00 billion, down from $1.09 billion a year earlier.

Analysts surveyed by FactSet expected $995 million.

Shares of the global logistics and shipping company were up nearly 5% in Friday's premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Forge Resources Reports Soil Studies, Pilot Drilling at Fully-Permitted Coal Project
Forge Resources Reports Soil Studies, Pilot Drilling at Fully-Permitted Coal Project
May 15, 2024
01:50 PM EDT, 05/15/2024 (MT Newswires) -- Forge Resources ( FRGGF ) said Wednesday it initiated comprehensive soil studies and pilot drilling at La Estrella, a fully-permitted coal project in Santander, Colombia. The main objective is to characterize the area and determine the stratigraphic profile of the subsoil, the company said. Key aspects include a technical report detailing soil study...
Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification
Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification
May 15, 2024
01:52 PM EDT, 05/15/2024 (MT Newswires) -- Takeda Pharmaceutical's ( TAK ) dengue vaccine TAK-003 received prequalification from the World Health Organization on Friday, the WHO said Wednesday. TAK-003, a vaccine containing weakened forms of four dengue virus strains, is recommended by the WHO for children aged 6 to 16 years in high-risk areas, administered in two doses with a...
Market Chatter: Nio Launches 1st Car Under Onvo Brand, Deliveries Set for September
Market Chatter: Nio Launches 1st Car Under Onvo Brand, Deliveries Set for September
May 15, 2024
01:52 PM EDT, 05/15/2024 (MT Newswires) -- Nio (NIO) launched L60 SUV, its first car under the new brand Onvo, with deliveries set for September, CNBC reported Wednesday. Presales for L60 SUV, which the company says will be about $4,000 cheaper than Tesla's (TSLA) comparable Model Y, started after the launch event, according to the report. Onvo will eventually start...
Virpax Prices Public Offering of Shares, Warrants; Shares Tumble
Virpax Prices Public Offering of Shares, Warrants; Shares Tumble
May 15, 2024
01:55 PM EDT, 05/15/2024 (MT Newswires) -- Virpax Pharmaceuticals ( VRPX ) shares tumbled more than 65% in recent Wednesday trading after the company priced its public offering of slightly more than 1.6 million common shares and related warrants at $1.35 each for gross proceeds of nearly $2.3 million. The five-year series A-1 and 18-month series A-2 warrants to buy...
Copyright 2023-2026 - www.financetom.com All Rights Reserved